Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Non Operating Income (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Non Operating Income for 4 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 2772.73% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, up 1626.22% year-over-year, with the annual reading at $1.5 million for FY2025, 1466.36% up from the prior year.
  • Non Operating Income hit $1.8 million in Q4 2025 for Taysha Gene Therapies, up from $1.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.8 million in Q4 2025 to a low of -$100.8 million in Q3 2023.
  • Historically, Non Operating Income has averaged -$8.7 million across 4 years, with a median of -$37000.0 in 2023.
  • Biggest five-year swings in Non Operating Income: plummeted 651616.67% in 2023 and later surged 3462.5% in 2024.
  • Year by year, Non Operating Income stood at -$6000.0 in 2022, then tumbled by 651616.67% to -$39.1 million in 2023, then surged by 99.83% to -$66000.0 in 2024, then surged by 2772.73% to $1.8 million in 2025.
  • Business Quant data shows Non Operating Income for TSHA at $1.8 million in Q4 2025, $1.3 million in Q3 2025, and -$237000.0 in Q2 2025.